Sage Therapeutics
SAGE
SAGE was delisted on the 30th of July, 2025.
197 hedge funds and large institutions have $411M invested in Sage Therapeutics in 2025 Q1 according to their latest regulatory filings, with 58 funds opening new positions, 51 increasing their positions, 53 reducing their positions, and 37 closing their positions.
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
57% more first-time investments, than exits
New positions opened: 58 | Existing positions closed: 37
48% more capital invested
Capital invested by funds: $278M → $411M (+$133M)
12% more funds holding
Funds holding: 176 → 197 (+21)
0.42% more ownership
Funds ownership: 83.74% → 84.15% (+0.42%)
4% less repeat investments, than reductions
Existing positions increased: 51 | Existing positions reduced: 53
20% less call options, than puts
Call options by funds: $2.1M | Put options by funds: $2.63M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MAP
Madison Avenue Partners
New York
|
+$32.8M |
| 2 |
TAL
TIG Advisors LLC
New York
|
+$20M |
| 3 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
+$14.9M |
| 4 |
Marshall Wace
London,
United Kingdom
|
+$12.9M |
| 5 |
D.E. Shaw & Co
New York
|
+$10M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$30.1M |
| 2 |
BG
Bellevue Group
Kuesnacht,
Switzerland
|
-$24.2M |
| 3 |
Morgan Stanley
New York
|
-$23.4M |
| 4 |
RI
RTW Investments
New York
|
-$16.3M |
| 5 |
Millennium Management
New York
|
-$9.62M |
SAGE Hedge Fund Activity: Q1 2025 in Review
197 of the 7,458 institutional investors tracked by Wall St. Rank reported a position in Sage Therapeutics (SAGE) for Q1 2025, worth a combined $411M — up 48% from $278M a quarter earlier.
Buyers outnumbered sellers: 58 funds opened new SAGE positions and 37 closed out — a net gain of 21 holders — while 51 added to existing stakes and 53 trimmed.
The largest buyer was Madison Avenue Partners, opening a new position worth an estimated $32.8M. The largest seller was Fidelity Investments, cutting an estimated $30.1M.
- 197 institutional investors held Sage Therapeutics (SAGE) as of Q1 2025, up from 176 in Q4 2024.
- Funds reported $411M of Sage Therapeutics stock for Q1 2025, up 48% quarter-over-quarter.
- 58 funds opened new Sage Therapeutics positions in Q1 2025 and 37 closed out, a net change of +21 holders.
- The largest Sage Therapeutics buyer in Q1 2025 was Madison Avenue Partners, an estimated $32.8M added.
- The largest Sage Therapeutics seller in Q1 2025 was Fidelity Investments, an estimated $30.1M sold.
Based on aggregated 13F filings for Q1 2025.